Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute
Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cance...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sehrawat, Amit [verfasserIn] Mittal, Gyanendra Swaroop [verfasserIn] Sundriyal, Deepak [verfasserIn] Chaturvedi, Anushree [verfasserIn] Gupta, Deni [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Indian Association of Surgical Oncology 2021 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Indian Journal of Surgical Oncology - Springer-Verlag, 2010, 12(2021), 2 vom: 05. März, Seite 246-250 |
|---|---|
| Übergeordnetes Werk: |
volume:12 ; year:2021 ; number:2 ; day:05 ; month:03 ; pages:246-250 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13193-021-01303-x |
|---|
| Katalog-ID: |
SPR044525915 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR044525915 | ||
| 003 | DE-627 | ||
| 005 | 20210711064735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210711s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13193-021-01303-x |2 doi | |
| 035 | |a (DE-627)SPR044525915 | ||
| 035 | |a (SPR)s13193-021-01303-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sehrawat, Amit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Indian Association of Surgical Oncology 2021 | ||
| 520 | |a Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. | ||
| 650 | 4 | |a Cancer-associated thromboembolism |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Venous thromboembolism |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Deep venous thrombosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Thromboprophylaxis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Venous access device |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mittal, Gyanendra Swaroop |e verfasserin |4 aut | |
| 700 | 1 | |a Sundriyal, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Chaturvedi, Anushree |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Deni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian Journal of Surgical Oncology |d Springer-Verlag, 2010 |g 12(2021), 2 vom: 05. März, Seite 246-250 |w (DE-627)SPR030797241 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:2 |g day:05 |g month:03 |g pages:246-250 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13193-021-01303-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 2 |b 05 |c 03 |h 246-250 | ||
| author_variant |
a s as g s m gs gsm d s ds a c ac d g dg |
|---|---|
| matchkey_str |
sehrawatamitmittalgyanendraswaroopsundri:2021----:acrsoitdeoshobeblsiabltrsldramlgacptetepre |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.1007/s13193-021-01303-x doi (DE-627)SPR044525915 (SPR)s13193-021-01303-x-e DE-627 ger DE-627 rakwb eng Sehrawat, Amit verfasserin aut Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. Cancer-associated thromboembolism (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Deep venous thrombosis (dpeaa)DE-He213 Thromboprophylaxis (dpeaa)DE-He213 Venous access device (dpeaa)DE-He213 Mittal, Gyanendra Swaroop verfasserin aut Sundriyal, Deepak verfasserin aut Chaturvedi, Anushree verfasserin aut Gupta, Deni verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 2 vom: 05. März, Seite 246-250 (DE-627)SPR030797241 nnns volume:12 year:2021 number:2 day:05 month:03 pages:246-250 https://dx.doi.org/10.1007/s13193-021-01303-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 2 05 03 246-250 |
| spelling |
10.1007/s13193-021-01303-x doi (DE-627)SPR044525915 (SPR)s13193-021-01303-x-e DE-627 ger DE-627 rakwb eng Sehrawat, Amit verfasserin aut Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. Cancer-associated thromboembolism (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Deep venous thrombosis (dpeaa)DE-He213 Thromboprophylaxis (dpeaa)DE-He213 Venous access device (dpeaa)DE-He213 Mittal, Gyanendra Swaroop verfasserin aut Sundriyal, Deepak verfasserin aut Chaturvedi, Anushree verfasserin aut Gupta, Deni verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 2 vom: 05. März, Seite 246-250 (DE-627)SPR030797241 nnns volume:12 year:2021 number:2 day:05 month:03 pages:246-250 https://dx.doi.org/10.1007/s13193-021-01303-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 2 05 03 246-250 |
| allfields_unstemmed |
10.1007/s13193-021-01303-x doi (DE-627)SPR044525915 (SPR)s13193-021-01303-x-e DE-627 ger DE-627 rakwb eng Sehrawat, Amit verfasserin aut Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. Cancer-associated thromboembolism (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Deep venous thrombosis (dpeaa)DE-He213 Thromboprophylaxis (dpeaa)DE-He213 Venous access device (dpeaa)DE-He213 Mittal, Gyanendra Swaroop verfasserin aut Sundriyal, Deepak verfasserin aut Chaturvedi, Anushree verfasserin aut Gupta, Deni verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 2 vom: 05. März, Seite 246-250 (DE-627)SPR030797241 nnns volume:12 year:2021 number:2 day:05 month:03 pages:246-250 https://dx.doi.org/10.1007/s13193-021-01303-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 2 05 03 246-250 |
| allfieldsGer |
10.1007/s13193-021-01303-x doi (DE-627)SPR044525915 (SPR)s13193-021-01303-x-e DE-627 ger DE-627 rakwb eng Sehrawat, Amit verfasserin aut Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. Cancer-associated thromboembolism (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Deep venous thrombosis (dpeaa)DE-He213 Thromboprophylaxis (dpeaa)DE-He213 Venous access device (dpeaa)DE-He213 Mittal, Gyanendra Swaroop verfasserin aut Sundriyal, Deepak verfasserin aut Chaturvedi, Anushree verfasserin aut Gupta, Deni verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 2 vom: 05. März, Seite 246-250 (DE-627)SPR030797241 nnns volume:12 year:2021 number:2 day:05 month:03 pages:246-250 https://dx.doi.org/10.1007/s13193-021-01303-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 2 05 03 246-250 |
| allfieldsSound |
10.1007/s13193-021-01303-x doi (DE-627)SPR044525915 (SPR)s13193-021-01303-x-e DE-627 ger DE-627 rakwb eng Sehrawat, Amit verfasserin aut Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. Cancer-associated thromboembolism (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Deep venous thrombosis (dpeaa)DE-He213 Thromboprophylaxis (dpeaa)DE-He213 Venous access device (dpeaa)DE-He213 Mittal, Gyanendra Swaroop verfasserin aut Sundriyal, Deepak verfasserin aut Chaturvedi, Anushree verfasserin aut Gupta, Deni verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 2 vom: 05. März, Seite 246-250 (DE-627)SPR030797241 nnns volume:12 year:2021 number:2 day:05 month:03 pages:246-250 https://dx.doi.org/10.1007/s13193-021-01303-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 2 05 03 246-250 |
| language |
English |
| source |
Enthalten in Indian Journal of Surgical Oncology 12(2021), 2 vom: 05. März, Seite 246-250 volume:12 year:2021 number:2 day:05 month:03 pages:246-250 |
| sourceStr |
Enthalten in Indian Journal of Surgical Oncology 12(2021), 2 vom: 05. März, Seite 246-250 volume:12 year:2021 number:2 day:05 month:03 pages:246-250 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Cancer-associated thromboembolism Venous thromboembolism Deep venous thrombosis Thromboprophylaxis Venous access device |
| isfreeaccess_bool |
false |
| container_title |
Indian Journal of Surgical Oncology |
| authorswithroles_txt_mv |
Sehrawat, Amit @@aut@@ Mittal, Gyanendra Swaroop @@aut@@ Sundriyal, Deepak @@aut@@ Chaturvedi, Anushree @@aut@@ Gupta, Deni @@aut@@ |
| publishDateDaySort_date |
2021-03-05T00:00:00Z |
| hierarchy_top_id |
SPR030797241 |
| id |
SPR044525915 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR044525915</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210711064735.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210711s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13193-021-01303-x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR044525915</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13193-021-01303-x-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sehrawat, Amit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Association of Surgical Oncology 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer-associated thromboembolism</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Venous thromboembolism</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Deep venous thrombosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thromboprophylaxis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Venous access device</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mittal, Gyanendra Swaroop</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sundriyal, Deepak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chaturvedi, Anushree</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gupta, Deni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgical Oncology</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">12(2021), 2 vom: 05. März, Seite 246-250</subfield><subfield code="w">(DE-627)SPR030797241</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">day:05</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:246-250</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13193-021-01303-x</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="b">05</subfield><subfield code="c">03</subfield><subfield code="h">246-250</subfield></datafield></record></collection>
|
| author |
Sehrawat, Amit |
| spellingShingle |
Sehrawat, Amit misc Cancer-associated thromboembolism misc Venous thromboembolism misc Deep venous thrombosis misc Thromboprophylaxis misc Venous access device Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute |
| authorStr |
Sehrawat, Amit |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR030797241 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute Cancer-associated thromboembolism (dpeaa)DE-He213 Venous thromboembolism (dpeaa)DE-He213 Deep venous thrombosis (dpeaa)DE-He213 Thromboprophylaxis (dpeaa)DE-He213 Venous access device (dpeaa)DE-He213 |
| topic |
misc Cancer-associated thromboembolism misc Venous thromboembolism misc Deep venous thrombosis misc Thromboprophylaxis misc Venous access device |
| topic_unstemmed |
misc Cancer-associated thromboembolism misc Venous thromboembolism misc Deep venous thrombosis misc Thromboprophylaxis misc Venous access device |
| topic_browse |
misc Cancer-associated thromboembolism misc Venous thromboembolism misc Deep venous thrombosis misc Thromboprophylaxis misc Venous access device |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Indian Journal of Surgical Oncology |
| hierarchy_parent_id |
SPR030797241 |
| hierarchy_top_title |
Indian Journal of Surgical Oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR030797241 |
| title |
Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute |
| ctrlnum |
(DE-627)SPR044525915 (SPR)s13193-021-01303-x-e |
| title_full |
Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute |
| author_sort |
Sehrawat, Amit |
| journal |
Indian Journal of Surgical Oncology |
| journalStr |
Indian Journal of Surgical Oncology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
246 |
| author_browse |
Sehrawat, Amit Mittal, Gyanendra Swaroop Sundriyal, Deepak Chaturvedi, Anushree Gupta, Deni |
| container_volume |
12 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sehrawat, Amit |
| doi_str_mv |
10.1007/s13193-021-01303-x |
| author2-role |
verfasserin |
| title_sort |
cancer-associated venous thromboembolism in ambulatory solid organ malignancy patients: experience from a cancer research institute |
| title_auth |
Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute |
| abstract |
Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. © Indian Association of Surgical Oncology 2021 |
| abstractGer |
Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. © Indian Association of Surgical Oncology 2021 |
| abstract_unstemmed |
Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. © Indian Association of Surgical Oncology 2021 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
2 |
| title_short |
Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute |
| url |
https://dx.doi.org/10.1007/s13193-021-01303-x |
| remote_bool |
true |
| author2 |
Mittal, Gyanendra Swaroop Sundriyal, Deepak Chaturvedi, Anushree Gupta, Deni |
| author2Str |
Mittal, Gyanendra Swaroop Sundriyal, Deepak Chaturvedi, Anushree Gupta, Deni |
| ppnlink |
SPR030797241 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13193-021-01303-x |
| up_date |
2024-07-04T01:07:37.145Z |
| _version_ |
1803608661319221248 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR044525915</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210711064735.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210711s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13193-021-01303-x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR044525915</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13193-021-01303-x-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sehrawat, Amit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Association of Surgical Oncology 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer-associated thromboembolism</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Venous thromboembolism</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Deep venous thrombosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thromboprophylaxis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Venous access device</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mittal, Gyanendra Swaroop</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sundriyal, Deepak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chaturvedi, Anushree</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gupta, Deni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgical Oncology</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">12(2021), 2 vom: 05. März, Seite 246-250</subfield><subfield code="w">(DE-627)SPR030797241</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">day:05</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:246-250</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13193-021-01303-x</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="b">05</subfield><subfield code="c">03</subfield><subfield code="h">246-250</subfield></datafield></record></collection>
|
| score |
7.4013157 |